Humoral Immune Responses after an Omicron-Adapted Booster BNT162b2 Vaccination in Patients with Lymphoid Malignancies
To accommodate waning COVID-19 vaccine immunity to emerging SARS-CoV-2 variants, variant-adapted mRNA vaccines have been introduced. Here, we examine serological responses to the BA.1 and BA.4-5 Omicron variant-adapted BNT162b2 COVID-19 vaccines in people with lymphoid malignancies. We included 233...
Main Authors: | , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Jezik: | English |
Izdano: |
MDPI AG
2023-12-01
|
Serija: | Viruses |
Teme: | |
Online dostop: | https://www.mdpi.com/1999-4915/16/1/11 |